title: Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.
abstract: Chronic myeloid leukemia (CML) is a hematological disease accounting for about 15-20% of all adult leukemias. The clinical and biologic advances achieved in such a malignancy, represent one of the best successes obtained by translational medicine. Indeed, identification of the fusion oncogene BCR-ABL has allowed using of small molecule inhibitors of its tyrosine kinase activity which, in turn, have literally revolutionized the treatment of CML. Importantly the successfully clinical management was also realized on appropriate diagnosis, disease monitoring as well as early identification of such mutations causing drug resistance. Notably the recent availability of refined laboratory equipments represented by the Next Generation Sequencing (NGS) and genomic analyses has further contributed to gain ground towards the cure of this tumor. These issues are discussed here together with an overview on how patients treated with tyrosine kinase inhibitors should be monitored.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02115, USA. antonia_cagnetta@dfci.harvard.edu.
authors.forename: Antonia
authors.initials: A
authors.lastname: Cagnetta
authors.forename: Anna
authors.initials: A
authors.lastname: Garuti
authors.forename: Carlo
authors.initials: C
authors.lastname: Marani
authors.forename: Michele
authors.initials: M
authors.lastname: Cea
authors.forename: Maurizio
authors.initials: M
authors.lastname: Miglino
authors.forename: Ilaria
authors.initials: I
authors.lastname: Rocco
authors.forename: Claudia
authors.initials: C
authors.lastname: Palermo
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Fugazza
authors.forename: Gabriella
authors.initials: G
authors.lastname: Cirmena
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Colombo
authors.forename: Raffaella
authors.initials: R
authors.lastname: Grasso
authors.forename: Alessio
authors.initials: A
authors.lastname: Nencioni
authors.forename: Marco
authors.initials: M
authors.lastname: Gobbi
authors.forename: Franco
authors.initials: F
authors.lastname: Patrone
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004252:DNA Mutational Analysis; D016903:Drug Monitoring; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D005820:Genetic Testing; D023281:Genomics / Q000379:methods; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D025202:Molecular Diagnostic Techniques; D058990:Molecular Targeted Therapy; D009154:Mutation; D018579:Patient Selection; D057285:Precision Medicine; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl